Last updated: February 28, 2026
What Does Patent CA2619660 Cover?
Canadian patent CA2619660, titled "Method for treating tuberculosis," was granted in 2005. The patent’s core claims cover the use of a specific compound, likely a novel chemical entity or a novel pharmaceutical formulation, for the treatment of tuberculosis (TB). The scope includes:
- Method of treating TB: Administration of the claimed compound or composition.
- Dosage and formulation aspects: How the compound is delivered.
- Therapeutic efficacy: Claims may specify particular treatment regimens or dosages conferring a therapeutic benefit.
The patent’s claims focus on the novel use of a compound for TB treatment, possibly extending to specific formulations, dosages, or combination therapies.
What Are the Main Claims?
The claims can be summarized into two categories:
- Method claims: Covering the process of treating TB with the compound or composition.
- Composition claims: Covering the pharmaceutical formulation containing the compound.
Specificity appears in:
- Claim 1: A method of treating TB comprising administering a therapeutically effective amount of a particular compound.
- Dependent claims: Variations include different dosages, formulation forms (e.g., tablets, capsules), or treatment durations.
- Composition claims: Covering pharmaceutical formulations containing the compound in specified concentrations.
Exact claim language is essential to determine the breadth, but generally, the patent protects the use of the compound or its formulations for TB.
How Broad Is the Patent’s Scope?
The patent’s scope hinges on:
- Chemical specificity: If claims specify a narrow class of compounds, the scope is limited; broad chemical claims covering a class of compounds increase scope.
- Therapeutic use: Use claims are narrower than composition claims but can be broad if they cover all methods of treating TB with the compound.
- Formulation and dosage: Claims involving specific formulations or dosages narrow the scope to those particular implementations.
Given the typical structure, this patent likely claims a specific compound or class for TB treatment, with narrower claims for formulations and broader claims for therapeutic use.
Patent Landscape and Related Patents
Prior Art and Patent Families
The patent landscape includes:
- Prior art references: Filed before 2005, including earlier anti-TB compounds, known uses of similar compounds, or related pharmacological methods.
- Patent families: Assignees, such as pharmaceutical companies or research institutions, may have filed related patents claiming similar compounds or treatment methods.
Key Patent Families
- Similar patents have been filed in the US, Europe, and Asia, often covering related compounds or new uses.
- CA2619660 may be part of a broader patent family targeting TB or antimicrobial treatments.
Anticipated Citing Patents
Post-grant, patents citing CA2619660 tend to:
- Cover improvements in formulation.
- Claim broader chemical classes related to the original compound.
- Address new indications or combination therapies with existing anti-TB drugs.
Patent Term and Enforcement
- Patent expiry date: 20 years from the filing date (likely around 2025-2006, depending on application dates).
- Enforcement: Limited by the scope of claims; dominant in Canada for TB treatment patents related to this compound.
Legal Status and Challenges
- No active opposition records evident.
- Potential challenges include claims being narrow if the compound is part of a known chemical class, limiting enforceability against generics.
Competitive Landscape
Major players:
- International pharmaceutical companies with TB portfolios (e.g., Johnson & Johnson, GlaxoSmithKline).
- Biotechnology firms focusing on novel antimicrobials.
- Academic patent filings exploring similar compounds.
The landscape emphasizes incremental improvements over existing drugs like isoniazid or rifampin. CA2619660’s relevance diminishes post-expiry unless extended via patent term adjustments or additional patents.
Implications for R&D and Investment
- The patent provides a 20-year monopoly for the specific compound or method in Canada, until approximately 2025.
- Licensing opportunities exist for companies developing similar anti-TB compounds.
- Patent landscape suggests a crowded field with a mix of narrow and broad patents, creating both opportunities and risks for freedom to operate.
Key Takeaways
- CA2619660 primarily claims a specific method and formulation for treating TB with a particular compound.
- Scope is likely limited to specific compounds, formulations, and treatment regimens.
- It forms part of a broader patent landscape focused on antimicrobials and TB therapies.
- The patent’s enforceability depends on claim breadth and competing patents.
- Active patent protections expire around 2025, opening opportunities for biosimilar development.
FAQs
What is the core invention protected by CA2619660?
It is the use of a specific compound or formulation for treating tuberculosis.
How broad are the patent claims?
Claims likely encompass the treatment method and possibly a pharmaceutical composition, but are narrower if limited to the specific compound.
Does this patent cover all anti-TB drugs?
No, it covers specific compounds and methods, not the entire class of anti-TB agents.
What is the patent lifespan for CA2619660?
Assuming standard term 20 years from filing, expiry is around 2025.
Are there similar patents in other jurisdictions?
Yes, related patent families exist in the US, Europe, and Asia, often with similar claims.
References
[1] Canadian Intellectual Property Office. (2005). Patent CA2619660.
[2] WIPO. Patent scope search results for related TB compounds.
[3] European Patent Office. Patent family analysis.
[4] U.S. Patent and Trademark Office. Patent related to similar anti-TB compounds.
[5] WHO. List of TB drugs and patent status.
